Tigen_up_to_Date.jpg

Stay up to date

We are moving fast and shaping the cell & gene landscape requires a lot of engagement amongst all stakeholders in the ecosystem.
We keep you informed about the latest news on Tigen and we would be delighted to get your feedback and your point of view.

News
Tigen_CHUV_option_2022.jpeg

Lausanne, 14 October 2022

Tigen exercises first option from the T Cell Program at the Centre hospitalier universitaire vaudois (CHUV) on behalf of the Ludwig Institute for Cancer Research for the development of a Neoantigen-specific Tumor Infiltrating Lymphocytes product (NeoTIL).
Bildschirmfoto 2022-10-11 um 21.04.35.png

Lausanne, 1 September 2022

Join us in welcoming Simon Eade as Chief Business Officer.
04_Tigen_Emily_Whitehead_13.jpg

Lausanne, 29 August 2022

Emily Whitehead Foundation, Bruce Levin and Stephan Grupp visiting the Tigen lab in Lausanne and discussing what's next in Cell & Gene Therapies.
Bioinsights_cgt_insights.png

Lausanne, 5 July 2022

Why we need a revolution for personalized cell therapies.
Tigen_Portrait_Simon_2022_02.jpg

Lausanne, 1 July 2022

Join us in welcoming Simon Chaplin as Chief Financial Officer.
Tigen_Advanced_Therapies_2022.jpeg

London, 25 May 2022

Dorothea Ledergerber discussing the future of cell & gene therapies manufacturing at the Advanced Therapies get-together in London.
Therese.jpg

Lausanne, 25 April 2022

Join us in welcoming Therese Choquette (Vallerskog) to the Tigen team as Head of Analytical Sciences.